Effect of inhaled Mucomyst and Hypertonic saline in Bronchiectasis

A Randomized and controlled crossover study investigating synergistic Effect of inhaled Mucomyst and Hypertonic saline in Bronchiectasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011672

Enrollment

Registered

2026-03-03

Start date

2023-12-05

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In this study, patients with bronchiectasis who exhibit daily sputum symptoms and visit the outpatient respiratory clinic will be randomly assigned to a control group (receiving distilled water

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Bronchiectasis in one or more lobes on chest CT Respiratory symptoms, including daily phlegm, persisting for the past 2 months or longer

Exclusion criteria

Exclusion criteria: Under 40 years of age Cystic fibrosis Previous pulmonary resection, heart or lung transplantation Pregnant or lactating women Current smokers Patients with active pulmonary tuberculosis or receiving treatment for nontuberculous mycobacteria Unwilling to participate in the study

Design outcomes

Primary

Measure	Time frame
Chest clearance VAS score	—

Secondary

Measure	Time frame
Cough, phlegm, dyspnea VAS score;Exacerbation of bronchiectasis	—

Countries

Korea, Republic of

Contacts

Public ContactRa Seung Won

Ulsan Univeristy Hospital

docra@docra.pe.kr+82-52-230-1438

Outcome results